Abstract
Despite adjuvant intravesical treatments, up to 40–50% of high-risk non-muscle invasive bladder cancer (NMIBC) patients will experience recurrence. The current evidence, due to the very aggressive behaviour of the disease, strongly recommends radical surgery for NMIBC patients failing intravesical immunotherapy (Bacillus Calmette-Guerin). However, on the other hand, radical surgery may sometimes represent an over-treatment, especially for those patients with non-high-grade recurrence. Moreover, some patients could be considered unfit for surgery due to the high comorbidity rates, as frequently observed in old patients. Therefore, the development of new adjuvant therapies, or at least the improvement of the existing ones is urgently needed. In the last years, several new device-assisted therapies have been developed with the aim to improve the effectiveness of intravesical chemotherapy by increasing its penetration into the bladder wall. Electromotive Drug Administration (EMDA) and chemo-hyperthermia (CHT) are, to date, the most investigated. Reported results are promising and showed that conservative therapies for high-risk NMIBC (CHT and EMDA) could represent a feasible and safe treatment, even if, due to the low level of evidence and to the lack of high-quality trials, remain, to date, experimental.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Gontero P, Bohle A, Malmstrom P-U, O’Donnell MA, Oderda M, Sylvester R, et al. The role of Bacillus Calmette-Guérin in the treatment of non-muscle-invasive bladder cancer. Eur Urol. 2010;57:410–29. https://doi.org/10.1016/j.eururo.2009.11.023.
Martin FM, Kamat AM. Definition and management of patients with bladder cancer who fail BCG therapy. Expert Rev Anticancer Ther. 2009;9:815–20. https://doi.org/10.1586/era.09.35.
Babjuk M, Böhle A, Burger M, Capoun O, Cohen D, Compérat EM, et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2016. Eur Urol. 2017;71:447–61. https://doi.org/10.1016/j.eururo.2016.05.041.
Phipps JB, Padmanabhan RV, Lattin GA. Iontophoretic delivery of model inorganic and drug ions. J Pharm Sci. 1989;78:365–9.
Kos B, Vásquez JL, Miklavčič D, Hermann GGG, Gehl J. Investigation of the mechanisms of action behind Electromotive Drug Administration (EMDA). Peer J. 2016;4:e2309. https://doi.org/10.7717/peerj.2309.
Di Stasi SM, Giannantoni A, Stephen RL, Capelli G, Navarra P, Massoud R, et al. Intravesical electromotive mitomycin C versus passive transport mitomycin C for high risk superficial bladder cancer: a prospective randomized study. J Urol. 2003;170:777–82. https://doi.org/10.1097/01.ju.0000080568.91703.18.
Di Stasi SM, Giannantoni A, Giurioli A, Valenti M, Zampa G, Storti L, et al. Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomised controlled trial. Lancet Oncol. 2006;7:43–51. https://doi.org/10.1016/S1470-2045(05)70472-1.
Gan C, Amery S, Chatterton K, Khan MS, Thomas K, O’Brien T. Sequential bacillus Calmette-Guérin/Electromotive Drug Administration of Mitomycin C as the standard intravesical regimen in high risk nonmuscle invasive bladder cancer: 2-year outcomes. J Urol. 2016;195:1697–703. https://doi.org/10.1016/j.juro.2016.01.103.
Di Stasi SM, Valenti M, Verri C, Liberati E, Giurioli A, Leprini G, et al. Electromotive instillation of mitomycin immediately before transurethral resection for patients with primary urothelial non-muscle invasive bladder cancer: a randomised controlled trial. Lancet Oncol. 2011;12(9):871. https://doi.org/10.1016/S1470-2045(11)70190-5.
Owusu RA, Abern MR, Inman BA. Hyperthermia as adjunct to intravesical chemotherapy for bladder cancer. Biomed Res Int. 2013;2013:262313. https://doi.org/10.1155/2013/262313.
Eppink B, Krawczyk PM, Stap J, Kanaar R. Hyperthermia-induced DNA repair deficiency suggests novel therapeutic anti-cancer strategies. Int J Hyperth. 2012;28:509–17. https://doi.org/10.3109/02656736.2012.695427.
Slater SE, Patel P, Viney R, Foster M, Porfiri E, James ND, et al. The effects and effectiveness of electromotive drug administration and chemohyperthermia for treating non-muscle invasive bladder cancer. Ann R Coll Surg Engl. 2014;96:415–9. https://doi.org/10.1308/003588414X13946184901001.
Colombo R, Da Pozzo LF, Salonia A, Rigatti P, Leib Z, Baniel J, et al. Multicentric study comparing intravesical chemotherapy alone and with local microwave hyperthermia for prophylaxis of recurrence of superficial transitional cell carcinoma. J Clin Oncol. 2003;21:4270–6. https://doi.org/10.1200/JCO.2003.01.089.
Colombo R, Salonia A, Leib Z, Pavone-Macaluso M, Engelstein D. Long-term outcomes of a randomized controlled trial comparing thermochemotherapy with mitomycin-C alone as adjuvant treatment for non-muscle-invasive bladder cancer (NMIBC). BJU Int. 2011;107:912–8. https://doi.org/10.1111/j.1464-410X.2010.09654.x.
Arends TJH, van der Heijden AG, Witjes JA. Combined chemohyperthermia: 10-year single center experience in 160 patients with nonmuscle invasive bladder cancer. J Urol. 2014;192:708–13. https://doi.org/10.1016/j.juro.2014.03.101.
Halachmi S, Moskovitz B, Maffezzini M, Conti G, Verweij F, Kedar D, et al. Intravesical mitomycin C combined with hyperthermia for patients with T1G3 transitional cell carcinoma of the bladder. Urol Oncol. 2011;29:259–64. https://doi.org/10.1016/j.urolonc.2009.02.012.
van der Heijden AG, Kiemeney LA, Gofrit ON, Nativ O, Sidi A, Leib Z, et al. Preliminary European results of local microwave hyperthermia and chemotherapy treatment in intermediate or high risk superficial transitional cell carcinoma of the bladder. Eur Urol. 2004;46:65–71; discussion 71-2. https://doi.org/10.1016/j.eururo.2004.01.019.
Alfred Witjes J, Hendricksen K, Gofrit O, Risi O, Nativ O. Intravesical hyperthermia and mitomycin-C for carcinoma in situ of the urinary bladder: experience of the European Synergo working party. World J Urol. 2009;27:319–24. https://doi.org/10.1007/s00345-009-0384-2.
Arends TJH, Nativ O, Maffezzini M, de Cobelli O, Canepa G, Verweij F, et al. Results of a randomised controlled trial comparing intravesical chemohyperthermia with Mitomycin C versus Bacillus Calmette-Guérin for adjuvant treatment of patients with intermediate- and high-risk non-muscle-invasive bladder cancer. Eur Urol. 2016;69(6):1046–52. https://doi.org/10.1016/j.eururo.2016.01.006.
Gofrit ON, Shapiro A, Pode D, Sidi A, Nativ O, Leib Z, et al. Combined local bladder hyperthermia and intravesical chemotherapy for the treatment of high-grade superficial bladder cancer. Urology. 2004;63:466–71. https://doi.org/10.1016/j.urology.2003.10.036.
Nativ O, Witjes JA, Hendricksen K, Cohen M, Kedar D, Sidi A, et al. Combined thermo-chemotherapy for recurrent bladder cancer after Bacillus Calmette-Guerin. J Urol. 2009;182:1313–7. https://doi.org/10.1016/j.juro.2009.06.017.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer International Publishing AG, part of Springer Nature
About this chapter
Cite this chapter
Allasia, M., Soria, F. (2018). The Role of New Experimental Conservative Therapies for High Risk Non-Muscle Invasive Bladder Cancer: Could We Trust Them?. In: Soria, F., Gontero, P. (eds) Treating Urothelial Bladder Cancer . Springer, Cham. https://doi.org/10.1007/978-3-319-78559-2_7
Download citation
DOI: https://doi.org/10.1007/978-3-319-78559-2_7
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-78558-5
Online ISBN: 978-3-319-78559-2
eBook Packages: MedicineMedicine (R0)